Excision BioTherapeutics announces positive preclinical data highlighting the safety, potency and development progress of the hepatitis B EBT-107 program at the ICE-HBV “Hepatitis B Cure Symposium”
Data highlight significant reduction in HBV DNA integration and other clinically-relevant biomarkers from the EBT-107 therapeutic candidate in preclinical mouse models.
Read the full company press release here.
Source : Excision BioTherapeutics, Inc.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.